APO Research
Talk to an analyst

APO RESEARCH · REPORT

Angiotensin Converting Enzyme (ACE) Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Research

Angiotensin Converting Enzyme (ACE) Inhibitors Industry Research Report 2026

20 December 2025129 pages

Choose your research edition.

Industry ResearchAngiotensin Converting Enzyme (ACE) Inhibitors Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Angiotensin Converting Enzyme (ACE) Inhibitors Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Angiotensin Converting Enzyme (ACE) Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Angiotensin Converting Enzyme (ACE) Inhibitors Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Angiotensin Converting Enzyme (ACE) Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Angiotensin Converting Enzyme (ACE) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Angiotensin Converting Enzyme (ACE) Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Angiotensin Converting Enzyme (ACE) Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Angiotensin Converting Enzyme (ACE) Inhibitors include Teva Pharmaceutical, Sanofi, Jhonson and Johnson, Novartis, Merck, Eli Lilly, Pfizer, GSK and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Angiotensin Converting Enzyme (ACE) Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (k tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k tons) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Angiotensin Converting Enzyme (ACE) Inhibitors Market by Company

Teva Pharmaceutical

Sanofi

Jhonson and Johnson

Novartis

Merck

Eli Lilly

Pfizer

GSK

Bayer

Bristol-Myers Squibb

Astra Zeneca

Abbott Laboratories

Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Type

Dicarboxylate-containing Agents

Sulfhydryl-containing Agents

Phosphonate-containing Agents

Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Application

Cardiovascular Diseases

Kidney Diseases

Hypertension

Other

Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiotensin Converting Enzyme (ACE) Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Angiotensin Converting Enzyme (ACE) Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiotensin Converting Enzyme (ACE) Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Angiotensin Converting Enzyme (ACE) Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Angiotensin Converting Enzyme (ACE) Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Angiotensin Converting Enzyme (ACE) Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Angiotensin Converting Enzyme (ACE) Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons) of Manufacturers (2021-2026) Table 7. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 8. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue of Manufacturers (2021-2026) Table 9. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Angiotensin Converting Enzyme (ACE) Inhibitors Average Price (US$/ton) of Manufacturers (2021-2026) Table 11. Global Angiotensin Converting Enzyme (ACE) Inhibitors Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Angiotensin Converting Enzyme (ACE) Inhibitors, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Angiotensin Converting Enzyme (ACE) Inhibitors, Product Type & Application Table 14. Global Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Angiotensin Converting Enzyme (ACE) Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Teva Pharmaceutical Company Information Table 19. Teva Pharmaceutical Business Overview Table 20. Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 21. Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 22. Teva Pharmaceutical Recent Developments Table 23. Sanofi Company Information Table 24. Sanofi Business Overview Table 25. Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 26. Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 27. Sanofi Recent Developments Table 28. Jhonson and Johnson Company Information Table 29. Jhonson and Johnson Business Overview Table 30. Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 31. Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 32. Jhonson and Johnson Recent Developments Table 33. Novartis Company Information Table 34. Novartis Business Overview Table 35. Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 36. Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 37. Novartis Recent Developments Table 38. Merck Company Information Table 39. Merck Business Overview Table 40. Merck Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 41. Merck Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 42. Merck Recent Developments Table 43. Eli Lilly Company Information Table 44. Eli Lilly Business Overview Table 45. Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 46. Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 47. Eli Lilly Recent Developments Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 51. Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 52. Pfizer Recent Developments Table 53. GSK Company Information Table 54. GSK Business Overview Table 55. GSK Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 56. GSK Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 57. GSK Recent Developments Table 58. Bayer Company Information Table 59. Bayer Business Overview Table 60. Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 61. Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 62. Bayer Recent Developments Table 63. Bristol-Myers Squibb Company Information Table 64. Bristol-Myers Squibb Business Overview Table 65. Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 66. Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 67. Bristol-Myers Squibb Recent Developments Table 68. Astra Zeneca Company Information Table 69. Astra Zeneca Business Overview Table 70. Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 71. Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 72. Astra Zeneca Recent Developments Table 73. Abbott Laboratories Company Information Table 74. Abbott Laboratories Business Overview Table 75. Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 76. Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 77. Abbott Laboratories Recent Developments Table 78. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 79. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2021-2026) & (k tons) Table 80. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Region (2021-2026) Table 81. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2027-2032) & (k tons) Table 82. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Region (2027-2032) Table 83. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 84. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Region (2021-2026) Table 85. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 86. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Region (2027-2032) Table 87. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2026) & (k tons) Table 89. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2027-2032) & (k tons) Table 90. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 91. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 92. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2026) & (k tons) Table 94. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2027-2032) & (k tons) Table 95. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 96. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 97. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2026) & (k tons) Table 99. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2027-2032) & (k tons) Table 100. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 101. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 102. South America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. South America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2026) & (k tons) Table 104. South America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2027-2032) & (k tons) Table 105. South America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 106. South America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 107. Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2026) & (k tons) Table 109. Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2027-2032) & (k tons) Table 110. Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 111. Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 112. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2026) & (k tons) Table 113. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2027-2032) & (k tons) Table 114. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2021-2026) Table 115. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2027-2032) Table 116. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 117. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 118. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2021-2026) Table 119. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2027-2032) Table 120. Global Angiotensin Converting Enzyme (ACE) Inhibitors Price by Type (2021-2026) & (US$/ton) Table 121. Global Angiotensin Converting Enzyme (ACE) Inhibitors Price by Type (2027-2032) & (US$/ton) Table 122. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2026) & (k tons) Table 123. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2027-2032) & (k tons) Table 124. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2021-2026) Table 125. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2027-2032) Table 126. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 127. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 128. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application (2021-2026) Table 129. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application (2027-2032) Table 130. Global Angiotensin Converting Enzyme (ACE) Inhibitors Price by Application (2021-2026) & (US$/ton) Table 131. Global Angiotensin Converting Enzyme (ACE) Inhibitors Price by Application (2027-2032) & (US$/ton) Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. Angiotensin Converting Enzyme (ACE) Inhibitors Distributors List Table 135. Angiotensin Converting Enzyme (ACE) Inhibitors Customers List Table 136. Angiotensin Converting Enzyme (ACE) Inhibitors Industry Trends Table 137. Angiotensin Converting Enzyme (ACE) Inhibitors Industry Drivers Table 138. Angiotensin Converting Enzyme (ACE) Inhibitors Industry Restraints Table 139. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Angiotensin Converting Enzyme (ACE) Inhibitors Product Image Figure 5. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size (2021-2032) & (US$ Million) Figure 7. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales (2021-2032) & (k tons) Figure 8. Global Angiotensin Converting Enzyme (ACE) Inhibitors Average Price (US$/ton) & (2021-2032) Figure 9. Dicarboxylate-containing Agents Product Image Figure 10. Sulfhydryl-containing Agents Product Image Figure 11. Phosphonate-containing Agents Product Image Figure 12. Cardiovascular Diseases Product Image Figure 13. Kidney Diseases Product Image Figure 14. Hypertension Product Image Figure 15. Other Product Image Figure 16. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Angiotensin Converting Enzyme (ACE) Inhibitors, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Angiotensin Converting Enzyme (ACE) Inhibitors Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region in 2025 Figure 22. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region in 2025 Figure 23. North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Country in 2025 Figure 24. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2021-2032) Figure 25. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country (2021-2032) Figure 26. United States Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Country in 2025 Figure 30. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2021-2032) Figure 31. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country (2021-2032) Figure 32. Germany Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Country in 2025 Figure 43. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country (2021-2032) Figure 45. China Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Country in 2025 Figure 54. South America Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2021-2032) Figure 55. South America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country (2021-2032) Figure 56. Brazil Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Country in 2025 Figure 60. Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country (2021-2032) Figure 62. Egypt Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2021-2032) Figure 68. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2021-2032) Figure 69. Global Angiotensin Converting Enzyme (ACE) Inhibitors Price (US$/ton) by Type (2021-2032) Figure 70. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2021-2032) Figure 71. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application (2021-2032) Figure 72. Global Angiotensin Converting Enzyme (ACE) Inhibitors Price (US$/ton) by Application (2021-2032) Figure 73. Angiotensin Converting Enzyme (ACE) Inhibitors Value Chain Figure 74. Angiotensin Converting Enzyme (ACE) Inhibitors Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Angiotensin Converting Enzyme (ACE) Inhibitors Industry Opportunities and Challenges

Scope & coverage.

Types
  • Dicarboxylate-containing Agents
  • Sulfhydryl-containing Agents
  • Phosphonate-containing Agents
Applications
  • Cardiovascular Diseases
  • Kidney Diseases
  • Hypertension
  • Other
Companies covered
  • Teva Pharmaceutical
  • Sanofi
  • Jhonson and Johnson
  • Novartis
  • Merck
  • Eli Lilly
  • Pfizer
  • GSK
  • Bayer
  • Bristol-Myers Squibb
  • Astra Zeneca
  • Abbott Laboratories

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size (2021-2032)
  4. 2.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales (2021-2032)
  5. 2.2.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Average Price (2021-2032)
  6. 2.3 Angiotensin Converting Enzyme (ACE) Inhibitors by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Dicarboxylate-containing Agents
  9. 2.3.3 Sulfhydryl-containing Agents
  10. 2.3.4 Phosphonate-containing Agents
  11. 2.4 Angiotensin Converting Enzyme (ACE) Inhibitors by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Cardiovascular Diseases
  14. 2.4.3 Kidney Diseases
  15. 2.4.4 Hypertension
  16. 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons) of Manufacturers (2021-2026)
  3. 3.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Angiotensin Converting Enzyme (ACE) Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Angiotensin Converting Enzyme (ACE) Inhibitors, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Angiotensin Converting Enzyme (ACE) Inhibitors, Product Type & Application
  8. 3.8 Global Manufacturers of Angiotensin Converting Enzyme (ACE) Inhibitors, Established Date
  9. 3.9 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Teva Pharmaceutical
  2. 4.1.1 Teva Pharmaceutical Company Information
  3. 4.1.2 Teva Pharmaceutical Business Overview
  4. 4.1.3 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  6. 4.1.5 Teva Pharmaceutical Recent Developments
  7. 4.2 Sanofi
  8. 4.2.1 Sanofi Company Information
  9. 4.2.2 Sanofi Business Overview
  10. 4.2.3 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  12. 4.2.5 Sanofi Recent Developments
  13. 4.3 Jhonson and Johnson
  14. 4.3.1 Jhonson and Johnson Company Information
  15. 4.3.2 Jhonson and Johnson Business Overview
  16. 4.3.3 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  18. 4.3.5 Jhonson and Johnson Recent Developments
  19. 4.4 Novartis
  20. 4.4.1 Novartis Company Information
  21. 4.4.2 Novartis Business Overview
  22. 4.4.3 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  24. 4.4.5 Novartis Recent Developments
  25. 4.5 Merck
  26. 4.5.1 Merck Company Information
  27. 4.5.2 Merck Business Overview
  28. 4.5.3 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  30. 4.5.5 Merck Recent Developments
  31. 4.6 Eli Lilly
  32. 4.6.1 Eli Lilly Company Information
  33. 4.6.2 Eli Lilly Business Overview
  34. 4.6.3 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  36. 4.6.5 Eli Lilly Recent Developments
  37. 4.7 Pfizer
  38. 4.7.1 Pfizer Company Information
  39. 4.7.2 Pfizer Business Overview
  40. 4.7.3 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  42. 4.7.5 Pfizer Recent Developments
  43. 4.8 GSK
  44. 4.8.1 GSK Company Information
  45. 4.8.2 GSK Business Overview
  46. 4.8.3 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  48. 4.8.5 GSK Recent Developments
  49. 4.9 Bayer
  50. 4.9.1 Bayer Company Information
  51. 4.9.2 Bayer Business Overview
  52. 4.9.3 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  54. 4.9.5 Bayer Recent Developments
  55. 4.10 Bristol-Myers Squibb
  56. 4.10.1 Bristol-Myers Squibb Company Information
  57. 4.10.2 Bristol-Myers Squibb Business Overview
  58. 4.10.3 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  60. 4.10.5 Bristol-Myers Squibb Recent Developments
  61. 4.11 Astra Zeneca
  62. 4.11.1 Astra Zeneca Company Information
  63. 4.11.2 Astra Zeneca Business Overview
  64. 4.11.3 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  66. 4.11.5 Astra Zeneca Recent Developments
  67. 4.12 Abbott Laboratories
  68. 4.12.1 Abbott Laboratories Company Information
  69. 4.12.2 Abbott Laboratories Business Overview
  70. 4.12.3 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  72. 4.12.5 Abbott Laboratories Recent Developments
5 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Scenario by Region
  1. 5.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region: 2021-2032
  3. 5.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region: 2021-2026
  4. 5.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region: 2027-2032
  5. 5.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region: 2021-2032
  6. 5.3.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region: 2021-2026
  7. 5.3.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region: 2027-2032
  8. 5.4 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Facts & Figures by Country
  9. 5.4.1 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2032)
  11. 5.4.3 North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Facts & Figures by Country
  16. 5.5.1 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2032)
  18. 5.5.3 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Angiotensin Converting Enzyme (ACE) Inhibitors Market Facts & Figures by Country
  41. 5.7.1 South America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2032)
  43. 5.7.3 South America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2032)
  2. 6.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2032) & (k tons)
  3. 6.1.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2021-2032)
  4. 6.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021-2032)
  5. 6.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2032)
  2. 7.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2032) & (k tons)
  3. 7.1.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2021-2032)
  4. 7.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021-2032)
  5. 7.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Angiotensin Converting Enzyme (ACE) Inhibitors Value Chain Analysis
  2. 8.1.1 Angiotensin Converting Enzyme (ACE) Inhibitors Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Angiotensin Converting Enzyme (ACE) Inhibitors Production Mode & Process
  5. 8.2 Angiotensin Converting Enzyme (ACE) Inhibitors Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Angiotensin Converting Enzyme (ACE) Inhibitors Distributors
  8. 8.2.3 Angiotensin Converting Enzyme (ACE) Inhibitors Customers
9 Global Angiotensin Converting Enzyme (ACE) Inhibitors Analyzing Market Dynamics
  1. 9.1 Angiotensin Converting Enzyme (ACE) Inhibitors Industry Trends
  2. 9.2 Angiotensin Converting Enzyme (ACE) Inhibitors Industry Drivers
  3. 9.3 Angiotensin Converting Enzyme (ACE) Inhibitors Industry Opportunities and Challenges
  4. 9.4 Angiotensin Converting Enzyme (ACE) Inhibitors Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst